SCHEMBL21802121

SCHEMBL21802121

CC(C)(C)[Si](C)(C)OC[C@@H]1C[C@@H](O[Si](C)(C)C(C)(C)C)CN1C(=O)O

nearest known ligand 0.33

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
PPM1D O15297 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15519418 0.89
SCHEMBL376274 0.89 PPM1D (0.33) PPM1D
SCHEMBL4301879 0.89 PPM1D (0.33) PPM1D
SCHEMBL3469089 0.89 PPM1D (0.33) PPM1D
SCHEMBL3433762 0.89 PPM1D (0.33) PPM1D
SCHEMBL4336670 0.89 PPM1D (0.33) PPM1D
SCHEMBL4292430 0.87 PPM1D (0.34) PPM1D
SCHEMBL2634064 0.86 PPM1D (0.34) PPM1D
SCHEMBL3470472 0.86 PPM1D (0.34) PPM1D
SCHEMBL5314317 0.86 PPM1D (0.34) PPM1D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3559007-B1 SULFONAMIDE COMPOUNDS HAVING TNAP INHIBITORY ACTIVITY DAIICHI SANKYO CO LTD (JP) 2023-08-16 EP disclosed
US-11046710-B2 Sulfonamide compounds DAIICHI SANKYO COMPANY, LIMITED (JP) 2021-06-29 US disclosed
US-11014939-B2 2021-05-25 US disclosed
US-20200087321-A1 SULFONAMIDE COMPOUNDS DAIICHI SANKYO COMPANY, LIMITED (JP) 2020-03-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200087321-A1 SULFONAMIDE COMPOUNDS ALPI, ASAH2, STS PPM1D 723/4885
US-11014939-B2 ALPI, ALPP, ACER2 PPM1D 1385/4885
US-11046710-B2 Sulfonamide compounds ALPI, ASAH2, STS PPM1D 723/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.